- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
J Thorac Oncol. 2018 Mar 10;:
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
J Clin Oncol. 2018 Feb 14;:JCO2017776385
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
ESMO Open. 2016;1(6):e000118
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for...
J Clin Oncol. 2018 Feb 05;:JCO2017767293
Expert Rev Respir Med. 2017 Nov 30;:
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 2017 Nov 09;:
Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population.
Carcinogenesis. 2017 Oct 20;:
Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Lancet Oncol. 2017 Oct 16;:
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Oncotarget. 2017 Sep 19;8(41):69651-69662
Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.
J Oncol Pract. 2017 Oct 05;:JOP2017027367
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group